Effect Of Recombinant Human Endostatin On Angiogenesis And Treatment Response Of Chemoradiotherapy For Patients With Esophageal Squamous Carcinoma

ObjectiveTo observe the effect of recombinant human endostatin (endostar) tochemoradiotherapy(CRT) in esophageal squamous carcinoma on vesselsparameters and treatment response, to expound the relationship betweenendostar and chemoradiation ensitivity in esophageal squamous carcinoma, forproviding the basis evidence for chemoradiation combined with endostar forpatients with esophageal cell squamous carcinoma (ESCC).MethodsA total of37ESCC patients confirmed by histopathology were randomlystudied.21patients were simultaneously treated with recombinant humanendostatin combined with docetaxel (60-75mg/m2on day1)/CDDP(20-25mg/m2on day1-3)-based intensity-modulated radiotherapy (IMRT,60-66Gy/30-33f/6-7w) and16patients were treated with docetaxel/CDDP-based IMRT alone. CT perfusion imaging responses of tumor bloodvessels, and immunohistochemical staining of tumor microvessel desity (MVD) before treatment and radiotherapy DT18-22Gy. The efficacy was evaluatedaccording to WHO RECIST criteria. The data were analyzed by two-samplet-test, Pearson correlation analysis and χ2test by SPSS l7.0statistical software,and P <0.05was considered to be significant.ResultsUpon completion of18-22Gy/10f/2w radiotherapy, chemotherapy andendostar in the first cycle were completed, in this case statistical parameters forblood vessel formation were analysised. The results showed that CT perfusionparameters in the experimental group and control group of BF, BV, MTT, PSand MVD counting difference had no statistical significance (P>0.05)beforetreatment, the former two with correction of MVD(P <0.05), that was meantwo groups of tumor angiogenesis were similar before treatment, and BF, BVcan state of tumor blood vessels on imaging. Endostar combined with CRT ledto a decrease in tumor blood flow (BF) and blood volume (BV) after treatment,compared to the CRT alone group (P<0.05) was found. Our findings showedevaluative patients a slight improvement in overall response rate(ORR)(61.5%(8/13)vs54.5%(6/11))(P>0．05).ConclusionEndostar combined with CRT can decrease ESCC tumor blood volume,reduce tumor angiogenesis, and the effects of recombinant human endostatincombined with CRT were a potential improvement over that of CRT alone.Further prospective randomised control studies are needed to evaluateconclusively the clinical efficacy of this combined treatment modality forESCC.